Does Atazanavir And Cobicistat Interact with Encorafenib?
CDI records a contraindicated classification for Atazanavir And Cobicistat and Encorafenib. The stored summary is: encorafenib ↓ atazanavir ↓ cobicistat ↑ encorafenib Coadministration with encorafenib is contraindicated due to the potential for loss of virologic response of EVOTAZ, development of resistance, and risk of serious adverse events such as QT interval prolongation. Mechanism: The mechanism of interaction is CYP3A4 induction by encorafenib. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Atazanavir And Cobicistat Class
- Cytochrome P450 3A Inhibitor
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Atazanavir And Cobicistat and your doctor is considering prescribing Encorafenib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider